What is the current valuation of the US Endometrial Cancer Market?

The US Endometrial Cancer Market was valued at 3.84 USD Billion in 2024. Read More

What is the projected market valuation for the US Endometrial Cancer Market by 2035?

The market is projected to reach 7.02 USD Billion by 2035. Read More

What is the expected CAGR for the US Endometrial Cancer Market during the forecast period 2025 - 2035?

The expected CAGR for the market during 2025 - 2035 is 5.63%. Read More

Which treatment types are included in the US Endometrial Cancer Market segments?

The market segments include Surgery, Radiation Therapy, Chemotherapy, and Hormonal Therapy. Read More

What were the valuations for Surgery in the US Endometrial Cancer Market from 2024 to 2035?

Surgery was valued at 1.15 USD Billion in 2024 and is projected to reach 2.05 USD Billion by 2035. Read More

How does the market perform by stage of cancer?

By stage, Stage I was valued at 1.15 USD Billion in 2024 and is expected to grow to 2.05 USD Billion by 2035. Read More

What are the key histological types contributing to the US Endometrial Cancer Market?

Key histological types include Endometrioid Carcinoma, Serous Carcinoma, Clear Cell Carcinoma, and Mixed Cell Carcinoma. Read More

What is the projected growth for Endometrioid Carcinoma in the market?

Endometrioid Carcinoma was valued at 1.92 USD Billion in 2024 and is anticipated to reach 3.42 USD Billion by 2035. Read More

What risk factors are associated with the US Endometrial Cancer Market?

Risk factors include Obesity, Age, Genetic Mutations, and Hormonal Factors. Read More

Which companies are the key players in the US Endometrial Cancer Market?

Key players include Merck & Co., Bristol-Myers Squibb, Pfizer Inc., and AstraZeneca. Read More

US Endometrial Cancer Market

ID: MRFR/MED/15168-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Endometrial Cancer Market Research Report: Size, Share, Trend Analysis By Types of Treatment (Surgery, Radiation Therapy, Chemotherapy, Hormonal Therapy, Targeted Therapy), By Diagnosis Method (Biopsy, Imaging Tests, Pelvic Exam, Endometrial Sampling), By End Users (Hospitals, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers) and By Stage of Cancer (Early Stage, Locally Advanced Stage, Metastatic Stage) - Growth Outlook & Industry Forecast 2025 To 2035

US Endometrial Cancer Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Treatment Type (USD Billion)
  1. 4.1.1 Surgery
  2. 4.1.2 Radiation Therapy
  3. 4.1.3 Chemotherapy
  4. 4.1.4 Hormonal Therapy
2. 4.2 Healthcare, BY Stage of Cancer (USD Billion)
  1. 4.2.1 Stage I
  2. 4.2.2 Stage II
  3. 4.2.3 Stage III
  4. 4.2.4 Stage IV
3. 4.3 Healthcare, BY Histological Type (USD Billion)
  1. 4.3.1 Endometrioid Carcinoma
  2. 4.3.2 Serous Carcinoma
  3. 4.3.3 Clear Cell Carcinoma
  4. 4.3.4 Mixed Cell Carcinoma
4. 4.4 Healthcare, BY Risk Factors (USD Billion)
  1. 4.4.1 Obesity
  2. 4.4.2 Age
  3. 4.4.3 Genetic Mutations
  4. 4.4.4 Hormonal Factors
5. 4.5 Healthcare, BY Diagnosis Method (USD Billion)
  1. 4.5.1 Ultrasound
  2. 4.5.2 Biopsy
  3. 4.5.3 MRI
  4. 4.5.4 CT Scan
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Merck & Co. (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Pfizer Inc. (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AstraZeneca (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Genentech (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Eli Lilly and Company (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Amgen Inc. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Bayer AG (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TREATMENT TYPE
3. 6.3 US MARKET ANALYSIS BY STAGE OF CANCER
4. 6.4 US MARKET ANALYSIS BY HISTOLOGICAL TYPE
5. 6.5 US MARKET ANALYSIS BY RISK FACTORS
6. 6.6 US MARKET ANALYSIS BY DIAGNOSIS METHOD
7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF HEALTHCARE
10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
13. 6.13 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
15. 6.15 HEALTHCARE, BY STAGE OF CANCER, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY STAGE OF CANCER, 2024 TO 2035 (USD Billion)
17. 6.17 HEALTHCARE, BY HISTOLOGICAL TYPE, 2024 (% SHARE)
18. 6.18 HEALTHCARE, BY HISTOLOGICAL TYPE, 2024 TO 2035 (USD Billion)
19. 6.19 HEALTHCARE, BY RISK FACTORS, 2024 (% SHARE)
20. 6.20 HEALTHCARE, BY RISK FACTORS, 2024 TO 2035 (USD Billion)
21. 6.21 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 (% SHARE)
22. 6.22 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Billion)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TREATMENT TYPE, 2026-2035 (USD Billion)
  2. 7.2.2 BY STAGE OF CANCER, 2026-2035 (USD Billion)
  3. 7.2.3 BY HISTOLOGICAL TYPE, 2026-2035 (USD Billion)
  4. 7.2.4 BY RISK FACTORS, 2026-2035 (USD Billion)
  5. 7.2.5 BY DIAGNOSIS METHOD, 2026-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Healthcare Market Segmentation

Healthcare By Treatment Type (USD Billion, 2026-2035)

Surgery
Radiation Therapy
Chemotherapy
Hormonal Therapy

Healthcare By Stage of Cancer (USD Billion, 2026-2035)

Stage I
Stage II
Stage III
Stage IV

Healthcare By Histological Type (USD Billion, 2026-2035)

Endometrioid Carcinoma
Serous Carcinoma
Clear Cell Carcinoma
Mixed Cell Carcinoma

Healthcare By Risk Factors (USD Billion, 2026-2035)

Obesity
Age
Genetic Mutations
Hormonal Factors

Healthcare By Diagnosis Method (USD Billion, 2026-2035)

Ultrasound
Biopsy
MRI
CT Scan

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”